AA
CORT icon

Ancora Advisors’s Corcept Therapeutics CORT Stock Holding History

Ancora Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,588
Closed -$542K – 2430
2025
Q4 		$542K Hold
15,588
– – 0.01% 518
2025
Q3 		$1.3M Sell
15,588
-600
-4% -$43.4K 0.03% 372
2025
Q2 		$1.19M Hold
16,188
– – 0.02% 372
2025
Q1 		$1.85M Hold
16,188
– – 0.04% 290
2024
Q4 		$816K Buy
16,188
+15,600
+2,653% +$817K 0.02% 442
2024
Q3 		$27.2K Hold
588
– – ﹤0.01% 1134
2024
Q2 		$19.1K Sell
588
-13,800
-96% -$378K ﹤0.01% 1174
2024
Q1 		$362K Buy
+14,388
New +$340K 0.01% 553

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Ancora Advisors's CORT Position: Q1 2026 in Review

Ancora Advisors sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 15,588 shares — an estimated $542K sold.

Ancora Advisors first reported a position in CORT in Q1 2024 and held it in 8 quarters. The position peaked at $1.85M in Q1 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Ancora Advisors reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ancora Advisors sold 15,588 Corcept Therapeutics shares in Q1 2026, an estimated $542K.
  • Ancora Advisors first reported a position in Corcept Therapeutics in Q1 2024 and held it in 8 quarters.
  • Ancora Advisors's Corcept Therapeutics position peaked at $1.85M in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.